Ryan Deschner
Stock Analyst at Raymond James
(4.80)
# 110
Out of 4,988 analysts
17
Total ratings
88.24%
Success rate
41.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $23.78 | +72.41% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $8.15 | +231.29% | 3 | Aug 8, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $54 | $58.24 | -7.28% | 1 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $6.21 | +93.24% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $23.01 | +117.30% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $25.40 | +380.31% | 1 | Jul 24, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $62 | $38.24 | +62.13% | 1 | Jul 14, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $9.79 | +186.01% | 3 | Jan 14, 2025 |
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $23.78
Upside: +72.41%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $8.15
Upside: +231.29%
Palvella Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $54
Current: $58.24
Upside: -7.28%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $6.21
Upside: +93.24%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $23.01
Upside: +117.30%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $25.40
Upside: +380.31%
Tvardi Therapeutics
Jul 14, 2025
Initiates: Outperform
Price Target: $62
Current: $38.24
Upside: +62.13%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $9.79
Upside: +186.01%